Evidence map›Paper›PMID 32823901›Full record

ReviewInternational journal of environmental research and public health2020

Understanding COVID-19: From Origin to Potential Therapeutics.

Muhammad Moazzam, Muhammad Imran Sajid, Hamza Shahid, Jahanzaib Butt, Irfan Bashir, Muhammad Jamshaid, Amir Nasrolahi Shirazi, Rakesh Kumar Tiwari

Open access · goldAbstract readReview
In one paragraph

Review in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Long COVID: a cross-sectional study of respiratory muscle strength, lung function, and persistent symptoms at one year after hospital discharge.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024
    Article
  3. Article
  4. Article
  5. Exploring Radiologists' Burnout in the COVID-19 Era: A Narrative Review.International journal of environmental research and public health · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Muhammad MoazzamFaculty of Pharmacy, University of Central Punjab, Lahore 54700, Pakistan.ORCID 0000-0003-4707-5440
Muhammad Imran SajidFaculty of Pharmacy, University of Central Punjab, Lahore 54700, Pakistan.
Hamza ShahidFaculty of Pharmacy, University of Central Punjab, Lahore 54700, Pakistan.
Jahanzaib ButtFaculty of Pharmacy, University of Central Punjab, Lahore 54700, Pakistan.
Irfan BashirFaculty of Pharmacy, University of Central Punjab, Lahore 54700, Pakistan.
Muhammad JamshaidFaculty of Pharmacy, University of Central Punjab, Lahore 54700, Pakistan.
Amir Nasrolahi ShiraziDepartment of Pharmaceutical Sciences, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA 92831, USA.
Rakesh Kumar TiwariCenter for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA 92618, USA.ORCID 0000-0003-3701-4548
University of Central Punjab · PKTarget (United States) · USMarshall B. Ketchum University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, a global pandemic era of public health concerns is going on with the Coronavirus Disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was reported from Wuhan's Huanan seafood market in China late December 2019. Bats, pangolins, and snakes have been nominated as salient carriers of the virus. Thanks to its high pathogenicity, it can cause severe respiratory infections. Fever, dry cough, sore throat, pneumonia, septic shock, and ground-glass opacities are the foremost clinical manifestations of COVID-19. Immunocompromised patients are at high risk for COVID-19 infection and may lead to death. Scientist and government agencies around the globe are putting forward their best efforts and resources for the effective treatment of human coronavirus infections; however, neither vaccines nor antiviral drugs are available for the treatment of human coronaviruses (HCoV) infections such as SARS (severe acute respiratory syndrome), MERS (Middle Eastern respiratory syndrome), and COVID-19. Since the outbreak, a plethora of research and review articles have been published. Moreover, the mass media has bombarded the public with conflicting opinions about the pandemic. There is a dire need for accurate and reliable information concerning this pandemic. In this review, we have compiled the up to date information about the origins, evolution, epidemiology, and pathogenesis of this disease. Moreover, very few reports have addressed the clinical features and current status of treatment for COVID-19; we have adequately addressed these topics in detail in this review. Finally, a detailed account of clinical trials of vaccines and other therapeutics currently in progress has been delineated.

Indexed as

Antiviral AgentsBetacoronavirusChinaCoronavirus InfectionsCOVID-19Disease OutbreaksHumansPandemicsPneumonia, ViralSARS-CoV-2Viral VaccinesAntiviral AgentsViral Vaccinesclinical featuresCOVID-19cytokine stormdexamethasoneepidemiologylife cyclepathogenesisremdesivirRT-PCRSARS-CoV-2therapeuticsvaccines

Identifiers

PMID32823901
PMCPMC7460442
OpenAlexW3049402770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.